✦ LIBER ✦

Chemotherapy of advanced non-small cell lung cancer

✍ Scribed by Bonnie J. Takasugi; Thomas P. Miller

Publisher: Springer US
Year: 1984
Tongue: English
Weight: 711 KB
Volume: 2
Category: Article
ISSN: 0167-6997
DOI: 10.1007/bf00175389

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cisplatin, vindesine and bleomycin (CVB)

Cisplatin, vindesine and bleomycin (CVB) combination chemotherapy of advanced non-small cell lung cancer

✍ Loretta M. Itri; Richard J. Gralla; David P. Kelsen; Robert A. Chapman; Ephraim 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 566 KB

Mitomycin C, vinblastine and cisplatin c

Mitomycin C, vinblastine and cisplatin combination chemotherapy in the treatment of advanced non-small cell lung cancer

✍ Fumio Nomura; Kaoru Shimokata; Hiroshi Saito; Shuzo Sakai; Atsushi Watanabe; Hid 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 277 KB

Combination versus sequential single-age

Combination versus sequential single-agent chemotherapy in the treatment of patients with advanced non-small cell lung cancer

✍ Niell, Harvey B. ;Griffin, John P. ;Hunter, Robert F. ;Meredith, Charlotte A. ;S 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 716 KB

We have carried out a randomized phase Ill study in 105 patients with advanced nonsmall cell lung cancer, comparing a fourdrug cisplatin-mitomycin-based combination chemotherapy regimen t o sequential single-agent therapy. The combination chemotherapy regimen consisted of mitomycin C (10 mg/m2), vin

Combination of chemotherapy and recombin

Combination of chemotherapy and recombinant alpha-interferon in advanced non-small cell lung cancer: Multicentric randomized FONICAP trial report

✍ Andrea Ardizzoni; Franco Salvati; Riccardo Rosso; Paolo Bruzzi; Alessandra Rubag 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 647 KB

Background. Preclinical data suggested that alphainterferon (IFN) may potentiate chemotherapy cytotoxicity. Methods. A prospective multicentric randomized trial was initiated to assess the clinical benefit of adding This work was conducted by the Italian Lung Cancer Task Force (FONICAP), which carr

A phase II study of methotrexate, doxoru

A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non-small cell lung cancer

✍ Gianfranco Buccheri; D. Ferrigno; A. Rosso 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 826 KB

Platinum-based combination chemotherapy

Platinum-based combination chemotherapy in advanced non-small cell lung cancer: A randomized phase II trial of the cancer and leukemia group B

✍ Green, Mark R. ;Kramar, Andrew ;Schilsky, Richard ;Stoopler, Marc ;Zimmer, Bonni 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 504 KB

## Abstract The Cancer and Leukemia Group B (CALGB) utilized a randomized phase II trial design to evaluate two cisplatin‐based combinations, cisplatin‐cytarabine (ara‐C) and cisplatin‐vinblastine, in 151 patients with advanced non‐small cell lung cancer. Patients entered on study had not received